Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

Exaclty, the science and trial results failed to meet expectations, hence very little interest from BP or institutional investors. At this point blaming shorts or managmemt is denial that ADXS has been a poor investment. If the science had showed promise, Berlin would have been in a position to strike a monetary deal and there would not have been a reverse and shorts would have been burnt.